|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The role for GPVI in platelet function in inflammation and in the evolution and treatment of major illnesses such as rheumatoid arthritis, cancer and sepsis is also discussed.
|
31351674 |
2019 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using a radiolabeled platelet glycoprotein VI-based ECM-targeting fusion protein (GPVI-Fc), we investigated how binding of GPVI-Fc on fibrous tissue could uncover the progression of several inflammatory disease models at different stages (rheumatoid arthritis, cutaneous delayed-type hypersensitivity, lung inflammation and experimental autoimmune encephalomyelitis).
|
31244929 |
2019 |
|
Acute Cerebrovascular Accidents
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glycoprotein (GP)Ib-mediated and GPVI-mediated platelet activation, but not GPIIb-IIIa-mediated platelet aggregation, is an important checkpoint that orchestrates thrombotic and pro-inflammatory pathways, and downstream activation of coagulation factor XII is a driving force of ischaemia-reperfusion injury in acute stroke.
|
31263257 |
2019 |
|
Acute Coronary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI.
|
31165998 |
2019 |
|
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Sarcoma family kinases (SFK) play central role in the GPVI-induced signaling pathway.
|
31683623 |
2019 |
|
Inflammatory disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Using a radiolabeled platelet glycoprotein VI-based ECM-targeting fusion protein (GPVI-Fc), we investigated how binding of GPVI-Fc on fibrous tissue could uncover the progression of several inflammatory disease models at different stages (rheumatoid arthritis, cutaneous delayed-type hypersensitivity, lung inflammation and experimental autoimmune encephalomyelitis).
|
31244929 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
The role for GPVI in platelet function in inflammation and in the evolution and treatment of major illnesses such as rheumatoid arthritis, cancer and sepsis is also discussed.
|
31351674 |
2019 |
|
Thrombotic Microangiopathies
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The plasma CLEC2 levels were poorly correlated with the levels of soluble GPVI in the plasma of patients with TMA.
|
30978634 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
Sarcoma family kinases (SFK) play central role in the GPVI-induced signaling pathway.
|
31683623 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Immunoreceptor tyrosine-based activation motif (ITAM) and hemi ITAM (hemITAM) comprising receptors, especially, glycoprotein VI (GPVI), FcγRIIa, and C-type lectin-like-2 receptor (CLEC-2) are turned in the spotlight since several new mechanisms and contributions to metastasis have been attributed to this family of platelet receptors in the last years.
|
30305116 |
2018 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The GPVI ligand collagen and the CLEC2 ligand podoplanin were constitutively present in the lung, whereas the GPVI ligands fibrin and histone were induced during pneumonia.
|
29187378 |
2018 |
|
Thrombasthenia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We developed a panel of 14 platelet-specific metal-tagged antibodies (targeting cluster of differentiation [CD] 9, CD29, CD31, CD36, CD41, CD42a, CD42b, CD61, CD62P, CD63, CD107a, CD154, glycoprotein [GP] VI and activated integrin αIIbβ3) and compared this panel with two fluorescence flow cytometry (FFC) panels (CD41, CD42b, and CD61; or CD42b, CD62P, and activated integrin αIIbβ3) in the evaluation of activation-dependent changes in glycoprotein expression on healthy subject and Glanzmann thrombasthenia (GT) platelets.
|
29985398 |
2018 |
|
Portal Vein Thrombosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Platelet Activation Assessed by Glycoprotein VI/Platelet Ratio Is Associated With Portal Vein Thrombosis After Hepatectomy and Splenectomy in Patients With Liver Cirrhosis.
|
29050501 |
2018 |
|
Autoimmune thrombocytopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
|
29695020 |
2018 |
|
Thrombocytopenia due to platelet alloimmunization
|
0.010 |
Biomarker
|
disease |
BEFREE |
Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
|
29695020 |
2018 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress.
|
27999100 |
2017 |
|
Seropositive rheumatoid arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that plasma levels of sGPVI would be increased among patients with seropositive RA as a consequence of antibody-induced platelet activation and GPVI shedding.
|
29141000 |
2017 |
|
Vascular inflammations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Platelets play a critical role in vascular inflammation through the podoplanin and collagen/fibrin receptors, C-type-lectin-like-2 (CLEC-2) and glycoprotein VI (GPVI), respectively.
|
29269852 |
2017 |
|
Compensated cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to use soluble GPVI levels to determine whether there was evidence for collagen and coagulation-induced platelet activation in early, well-compensated cirrhosis.
|
27416950 |
2017 |
|
Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation.
|
27416950 |
2017 |
|
Heparin-induced thrombocytopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we present some new data investigating whether levels of the extracellular ligand-binding region of platelet glycoprotein VI which is rapidly shed upon engagement of platelet FcγRIIa by autoantibodies, can report on the presence of pathological anti-heparin/platelet factor 4 immune complexes and thus identify patients with pathological autoantibodies who are at the greatest risk of developing life-threatening thrombosis in the setting of heparin-induced thrombocytopenia.
|
26497525 |
2015 |
|
Chest Pain
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Increased GPVI levels are associated with poor clinical outcome and are an early indicator for imminent myocardial infarction in patients with chest pain.
|
24553806 |
2014 |
|
Vascular lesions
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Non-invasive imaging studies with radiolabelled sGPVI-Fc show specific binding activity to vascular lesions in vivo.
|
24553806 |
2014 |
|
Miscarriage
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that variants of GP6 SNPs, namely, rs1671153, rs1654410, rs1654419, and rs1613662, may be associated with risk of recurrent miscarriage.
|
25086789 |
2014 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This demonstrates that the SNPs tested within the GPVI gene are not associated with RA susceptibility and/or severity, suggesting that platelet GPVI may contribute to arthritis independently of its gene polymorphism.
|
23739280 |
2013 |